Co-chaperones reported as supporting the development of AD include CDC37, p23, Aha1, FKBP52, and FKBP51, while co-chaperones such as CHIP and PP5 may help limit disease progression, a topic that has recently been reviewed.21, 54, 55 However, understanding how to modulate an imbalanced network to prevent the development of disease is not only difficult but it is a critical and an essential starting point for the successful development of drugs that can improve the prognosis of AD. Here, FKBP4 is linked to Alzheimer disease.